Cargando…

Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies

Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Davies, Jessica, Patel, Manali, Gridelli, Cesare, de Marinis, Filippo, Waterkamp, Daniel, McCusker, Margaret E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391942/
https://www.ncbi.nlm.nih.gov/pubmed/28410405
http://dx.doi.org/10.1371/journal.pone.0175679
_version_ 1783229368118542336
author Davies, Jessica
Patel, Manali
Gridelli, Cesare
de Marinis, Filippo
Waterkamp, Daniel
McCusker, Margaret E.
author_facet Davies, Jessica
Patel, Manali
Gridelli, Cesare
de Marinis, Filippo
Waterkamp, Daniel
McCusker, Margaret E.
author_sort Davies, Jessica
collection PubMed
description Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC. In light of these approvals, it is valuable to understand the uptake of these new treatments in routine clinical practice and their impact on patient care. A systematic literature search was conducted in multiple scientific databases to identify observational cohort studies published between January 2010 and March 2017 that described second- or third-line treatment patterns and clinical outcomes in patients with advanced NSCLC. A qualitative data synthesis was performed because a meta-analysis was not possible due to the heterogeneity of the study populations. A total of 12 different study cohorts in 15 articles were identified. In these cohorts, single-agent chemotherapy was the most commonly administered treatment in both the second- and third-line settings. In the 5 studies that described survival from the time of second-line treatment initiation, median overall survival ranged from 4.6 months (95% CI, 3.8–5.7) to 12.8 months (95% CI, 10.7–14.5). There was limited information on the use of biomarker-directed therapy in these patient populations. This systematic literature review offers insights into the adoption of novel therapies into routine clinical practice for second- and third-line treatment of patients with advanced NSCLC. This information provides a valuable real-world context for the impact of recently approved treatments for advanced NSCLC.
format Online
Article
Text
id pubmed-5391942
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-53919422017-05-03 Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies Davies, Jessica Patel, Manali Gridelli, Cesare de Marinis, Filippo Waterkamp, Daniel McCusker, Margaret E. PLoS One Research Article Most patients with advanced non-small cell lung cancer (NSCLC) have a poor prognosis and receive limited benefit from conventional treatments, especially in later lines of therapy. In recent years, several novel therapies have been approved for second- and third-line treatment of advanced NSCLC. In light of these approvals, it is valuable to understand the uptake of these new treatments in routine clinical practice and their impact on patient care. A systematic literature search was conducted in multiple scientific databases to identify observational cohort studies published between January 2010 and March 2017 that described second- or third-line treatment patterns and clinical outcomes in patients with advanced NSCLC. A qualitative data synthesis was performed because a meta-analysis was not possible due to the heterogeneity of the study populations. A total of 12 different study cohorts in 15 articles were identified. In these cohorts, single-agent chemotherapy was the most commonly administered treatment in both the second- and third-line settings. In the 5 studies that described survival from the time of second-line treatment initiation, median overall survival ranged from 4.6 months (95% CI, 3.8–5.7) to 12.8 months (95% CI, 10.7–14.5). There was limited information on the use of biomarker-directed therapy in these patient populations. This systematic literature review offers insights into the adoption of novel therapies into routine clinical practice for second- and third-line treatment of patients with advanced NSCLC. This information provides a valuable real-world context for the impact of recently approved treatments for advanced NSCLC. Public Library of Science 2017-04-14 /pmc/articles/PMC5391942/ /pubmed/28410405 http://dx.doi.org/10.1371/journal.pone.0175679 Text en © 2017 Davies et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Davies, Jessica
Patel, Manali
Gridelli, Cesare
de Marinis, Filippo
Waterkamp, Daniel
McCusker, Margaret E.
Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
title Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
title_full Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
title_fullStr Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
title_full_unstemmed Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
title_short Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies
title_sort real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5391942/
https://www.ncbi.nlm.nih.gov/pubmed/28410405
http://dx.doi.org/10.1371/journal.pone.0175679
work_keys_str_mv AT daviesjessica realworldtreatmentpatternsforpatientsreceivingsecondlineandthirdlinetreatmentforadvancednonsmallcelllungcancerasystematicreviewofrecentlypublishedstudies
AT patelmanali realworldtreatmentpatternsforpatientsreceivingsecondlineandthirdlinetreatmentforadvancednonsmallcelllungcancerasystematicreviewofrecentlypublishedstudies
AT gridellicesare realworldtreatmentpatternsforpatientsreceivingsecondlineandthirdlinetreatmentforadvancednonsmallcelllungcancerasystematicreviewofrecentlypublishedstudies
AT demarinisfilippo realworldtreatmentpatternsforpatientsreceivingsecondlineandthirdlinetreatmentforadvancednonsmallcelllungcancerasystematicreviewofrecentlypublishedstudies
AT waterkampdaniel realworldtreatmentpatternsforpatientsreceivingsecondlineandthirdlinetreatmentforadvancednonsmallcelllungcancerasystematicreviewofrecentlypublishedstudies
AT mccuskermargarete realworldtreatmentpatternsforpatientsreceivingsecondlineandthirdlinetreatmentforadvancednonsmallcelllungcancerasystematicreviewofrecentlypublishedstudies